An up­sized IPO? In this econ­o­my? Of course; Sofinno­va and Ab­b­Vie lead $38M Se­ries A for Parkin­son’s start­up

→ Sofinno­va and Ab­b­Vie Ven­tures have led a $38 mil­lion Se­ries A for Ni­trome Bio­sciences, a biotech that is de­vel­op­ing en­zymes to tar­get Parkin­son’s and oth­er age-re­lat­ed dis­eases. The com­pa­ny will be led by Irene Gris­wold-Pren­ner, who pre­vi­ous­ly ran neu­ro­bi­ol­o­gy at iP­ier­ian, de­vel­op­ing a tau-tar­get­ing an­ti­body that was lat­er at the cen­ter of a $725 mil­lion buy­out by Bris­tol-My­ers Squibb. The com­pa­ny has not said what en­zymes they will tar­get, but last year Gris­wold-Pren­ner re­ceived a grant from the Michael J. Fox Foun­da­tion to se­quence an en­zyme they called synu­cle­in ni­trase. The goal was to de­vel­op a drug tar­get­ing al­pha-synu­cle­in ni­tra­tion and ag­gre­ga­tion, which has been shown to play a role in the de­vel­op­ment of Parkin­son’s.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER